Bot Chart, page-155

I would suggest that the importance of the phase 1b psoriasis results should not be underestimated. This life long disease is severely disruptive for the patient and if we come up with superior data, we are onto the next big thing. Methotrexate is often used, so is plaquenil. Many injectable TNF Drugs are out there too and no wonder Humiras owners are crapping their pants with a bioaimilar currently available. These come in over or close to one grand a month. Our product, with an obvious safer profile could be a wonderful disruptor. Cbd as a buccal mouth spray is starting to take off for pain management so to get in First at the ground floor with skin ailments would be very nice.

Also notice all of these management appointees occurred in this phase 1b psoriasis stage, which was not double blind. Do you think the company may be happy with the imminent results and so got on the front foot with new marketing appointees?

Does a bear sheet in the forest?

I hope yes to both.